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Introduction
The United States is in the midst of a public health epidemic involving opioid use. In
particular, prescription pain reliever use has drastically increased. From 2000 to 2010, opioids
prescribed to US patients increased by 104% to a total of 89.2 million prescriptions (Clark &
Schumacher, 2017). According to the 2015 National Survey on Drug Use and Health (NSDUH),
roughly four million people aged 12 or older were current misusers of prescription opioids
(Center for Behavioral Health Statistics and Quality (CBHSQ), 2016). Two million people had a
pain reliever use disorder in 2015, yet only 800,000 received treatment (CBHSQ, 2016).
Although less common, heroin use in 2013 was higher than it was ten years ago (Lipari &
Hughes, 2014). Over half a million people had heroin dependence defined by the Diagnostic and
Statistical Manual of Mental Disorders 4th Edition (DSM-IV), yet only half of these individuals
received treatment at a specialty facility, such as a hospital, rehabilitation facility, or mental
health facility (CBHSQ, 2016).
The opioid epidemic has had devastating consequences. According to the Department of
Health and Human Services, over 130 people died every day from opioid-related drug overdoses
from 2016 to 2017 (U.S. Department of Health & Human Services, 2018). The opioid crisis is
estimated to have cost the United States over $1 trillion from 2001 to 2017 and will cost an
additional $500 billion by 2020 (Altarum, 2018). These costs are estimated from lost wages, lost
productivity, healthcare costs, lost tax revenue, as well as additional spending on criminal
justice, social services, and education (Altarum, 2018). With the growing costs as well as
prevalence of opioid use and undertreatment of opioid use disorder (OUD), it is essential that
treatment is available and accessible to all who may require it.
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Specific Aims:
The aim of this study was to use the 2017 NSDUH to answer the following questions:
1.) What are the characteristics of individuals who have OUD due to either pain reliever
misuse or heroin use?
2.) Among those identified with OUD, what are the characteristics of individuals
utilizing treatment for this substance use disorder?
3.) What types of treatment did persons with OUD access?
4.) What are the reasons why individuals with OUD do not enter substance abuse
treatment?
Ultimately, the research goal was to identify the characteristics of those with OUD underutilizing treatment in an effort to inform interventions aimed at improving access to treatment.

Background
Certain populations are known to be at risk for opioid misuse as well as developing OUD.
This includes individuals with a prior history of substance use disorder (SUD), younger age,
males, individuals with more severe pain, and individuals with co-occurring mental disorders
(Kaye et al., 2017). There are also many characteristics that influence the utilization of treatment
for OUD. As the opioid epidemic continues to expand and change, it is important to maintain
up-to-date knowledge on the scope of the problem as well as who it may disproportionately
impact.

Demographics:
Gender:
2

Male gender is considered a risk factor for misuse and death from opioid overdose (Rudd, Seth,
David, & Scholl, 2016). From the 2005 through 2013 NSDUH data, the majority (58%) of
persons with OUD were male (Wu, Zhu, & Swartz, 2016). The same analysis showed that
females with OUD were more likely to receive treatment in the past year, although the findings
were not statistically significant (Wu et al., 2016). Females with prescription opioid use disorder
have greater functional impairment and more co-occurring psychiatric conditions than their male
counterparts, which may increase referral and utilization of treatment for OUD (John & Wu,
2019). Women are more likely to access healthcare, which grants more opportunities for referral
to treatment (John & Wu, 2019).

Race/ethnicity:
The opioid epidemic has disproportionately affected whites living in rural areas or who have
low-income (Wu et al., 2016). According to data from the 2005-2013 NSDUH, whites
represented 72% of persons with OUD (Wu et al., 2016). The same analysis suggests that more
whites with OUD enter treatment while blacks and Native-Hawaiians/Pacific-Islanders/AsianAmericans underutilize opioid-specific treatment (Wu et al., 2016). Only 1.24% of NativeHawaiians/Pacific-Islanders/Asian-Americans with OUD received opioid-specific treatment,
making this demographic group the lowest utilizer of OUD treatment (Wu et al., 2016).

Socioeconomic Status:
Income:
Individuals with low-income have been impacted tremendously by the burden of OUD (Wu et
al., 2016). In prescription drug monitoring program data from 2011 through 2015, the majority
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of opioids prescribed in California were to adults living in regions with the lowest-income
(Friedman et al., 2019). This suggests that there might be a socioeconomic bias in prescription
patterns for opioids leading to the increased burden of OUD on lower-income individuals.
There is also inadequate access to substance treatment resources in low-income areas (Wu et al.,
2016). The loss of productivity associated with OUD as well as the high cost of opioids often
leads to a worsening financial situation for the individual impacted by the disease and their
family, thus making it difficult to afford treatment (Hansen et al., 2011).

Health insurance:
Although lack of insurance is associated with under-utilization of substance use treatment (Wu et
al., 2016), even privately insured individuals may be at risk of inadequate treatment(Ali &
Mutter, 2013). According to a report from the CBHSQ, patients with private insurance received
limited follow-up services after opioid-related hospitalizations (Ali & Mutter, 2013). Forty
percent of privately insured individuals who were hospitalized for reasons related to opioids did
not receive any follow-up services such as medication or therapy (Ali & Mutter, 2013). Rather
than due to the financial burden, inadequate referral to treatment after hospitalization may be due
to barriers, such as stigma surrounding illicit drug use, lack of perceived treatment need, or lack
of knowledge of appropriate therapies (Robinson & Adinoff, 2018). An analysis of data from
the 1997 National Household Survey on Drug Abuse found that persons having private insurance
did not differ from those with no insurance in predicting treatment for SUD (Wu, Ringwalt, &
Williams, 2003). Published analyses exist for data that predates the Affordable Care Act, which
led to millions of people gaining coverage. Further studies need to be conducted to see if
expansion of health insurance has impacted treatment utilization for OUD.
4

Depression:
The relationship between mental health and opioid use is complex. It is known, however,
that adults with mental health disorders receive more than half of the total opioids prescribed in
the US (Davis, Lin, Liu, & Sites, 2017). More specifically, depressive symptoms are associated
with increased rates of self-reported opioid misuse in patients with no previous history of
substance abuse (Grattan, Sullivan, Saunders, Campbell, & Von Korff, 2012). In a review of the
NSDUH from 2005 through 2013, 29% of persons with OUD had a major depressive episode
(MDE) in the past year based on DSM-IV criteria (Wu et al., 2016). Having a MDE in the past
year was associated with increased odds of utilizing opioid-specific treatment (Wu et al., 2016).

Employment:
According to the 2015 NSDUH, the majority of people with OUD were unemployed
(Han et al., 2017). Interestingly, Becker et al. (2008) found that unemployment was associated
with treatment receipt for those with OUD. The authors hypothesized that there is a higher
severity of OUD in those who are unemployed that requires attention for treatment. Severity of
OUD may also lead to unemployment. Another hypothesis to explain increased treatment with
unemployment is that those employed may have private insurance that may have more restrictive
coverage of services, which could discourage affected addicts from receiving treatment (Ali &
Mutter, 2013).

Criminal Justice Involvement:
Over one-third of US adults involved in the criminal justice system have SUD (Saloner,
Bandara, McGinty, & Barry, 2016), including higher rates of OUD and overdose (Krawczyk,
5

Picher, Feder, & Saloner, 2017). Criminal justice reform, as well as the Affordable Care Act
expansion of Medicaid, have improved access to and coverage for treatment for these individuals
over the past five years (Saloner et al., 2016). Through increased referral to treatment for SUD,
the criminal justice system seeks to reduce recidivism (Saloner et al., 2016).
The literature shows that certain characteristics of persons with OUD act as either
supports or barriers to substance use treatment utilization. This includes demographics (such as
age, gender, and race/ethnicity), health insurance, history of depression, employment status, and
criminal justice involvement. Although analyses of previous NSDUH data (2005-2013) supports
the associations of these characteristics with treatment utilization, limited research has examined
more recent NSDUH data. This study analyzed 2017 NSDUH data to provide current
verification of the characteristics related to treatment utilization for OUD. By identifying the
demographics/characteristics of those with OUD utilizing treatment, interventions that are aimed
at improving access to treatment may be better informed.

Methodology
Data Source:
The study was a secondary analysis of the data from the 2017 NSDUH, which is a
representative survey of the US population sponsored SAMHSA. The NSDUH collects data
through face-to-face interviews with residents of households who are US civilians, older than 12,
and not institutionalized. This survey does not include individuals who live in group residencies,
such as shelters, rooming houses, dorms, and military bases. The survey excludes people who
are homeless, in jails, or in hospitals. The sample size includes over 70,000 participants annually.
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The analysis sought to describe the relationship of certain characteristics of persons with OUD
who did or did not receive opioid use treatment.
The 2017 NSDUH data was downloaded as an SPSS file from the SAMHSA website. A total of
56,276 persons aged ≥12 completed the survey interview. The 2017 NSDUH codebook and
questionnaire were also downloaded to identify variables used to select cases of interest. From
the full data set, cases of adults 18 years or older were selected and extracted. From the adults,
cases were selected that had reported using heroin and/or prescription pain reliever misuse in the
past year. Individuals with OUD were then selected and extracted from this data set, in which
the NSDUH identified individuals as having heroin and/or pain reliever dependence or abuse in
the past year based on their answers to survey questions. The type of OUD (HUD, Rx OUD, or
both) as well as characteristics of individuals with past-year OUD were described. OUD is a
diagnosis defined currently by the DSM-V as two or more of the criterion checked in Table 1.
For more accurate comparisons to previous NSDUH data, the 2017 NSDUH continued to use the
DSM-IV for diagnosing opioid abuse (one or more the criterion checked in Table 1) and opioid
dependence (three or more of the criterion checked in Table 1). OUD in the 2017 NSDUH is
defined as opioid abuse and/or dependence.
Table 1: DSM-IV and DSM-V Criteria for Opioid Abuse, Opioid Dependence, and Opioid Use
Disorder
DSM-IV Opioid
DSM-IV Opioid
DSM-V Opioid Use
Abuse
Dependence
Disorder
Hazardous Use
X
X
Social/Interpersonal
X
X
Problems
Neglected Major
X
X
Roles
Legal Problems
X
Withdrawal
X
X
Tolerance
X
X
7

Use larger amounts
longer
Repeated attempts to
quit
Much time spent using
Physical/psychological
problem related to use
Activities given up to
use
Craving

X

X

X

X

X
X

X
X

X

X

X

X

Study Variables:
Independent variables used in the analysis were selected based upon support from the
literature. Age was recoded into three categories, including “18-29”, “30-49”, and “50+”.
Gender was dichotomized into males and females. Race/ethnicity was recoded into “White vs.
Non-white”, “White vs. Black/African American”, and “White vs. Hispanic”. Health insurance
variables were dichotomized into “yes vs. no” categories for each type of insurance, including
private insurance, public insurance, and no insurance. Public insurance included any individuals
with Medicaid, Medicare, or Tricare/CHAMPUS. Employment was dichotomized and measured
as employed in the past year (including partially employed) compared to unemployed in the past
year. The NSDUH variable for a major depressive episode (MDE) in the past year remained as a
dichotomous “yes vs. no” measure. The NSDUH utilizes computer-assisted interviewing (CAI)
instrumentation to determine whether a respondent has experienced a MDE in the past year or
their lifetime based on DSM-IV criteria. Criminal justice involvement was measured as “yes vs.
no” for being arrested and booked in the past year, excluding minor traffic violations. The
number of times arrested and booked in the past year was also used for analysis as a categorical
variable including “none”, “one time”, “two times”, and “three or more times”. In the NSDUH,
individuals were only asked how many times they had been arrested and booked in the past year
8

if they answered “yes” to being arrested and booked in the past year. The outcome variable was
receipt of treatment for drug use in the past year at any location (“yes vs. no”). This variable was
independent of treatment for alcohol use.
Data analysis:
Descriptive and logistic regression analyses were performed in SPSS to characterize
differences between individuals with OUD who received drug use treatment in the past year and
those with OUD who did not. Descriptive analyses were also performed to identify where
individuals received treatment as well as the reasons reported for why individuals did not receive
treatment.

Figure 1: Model outlining the key characteristics associated with OUD treatment utilization.
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Results
Population of Opioid Users:
Table 2: Frequency of Opioid Use in the Past Year among Persons Aged 18 or Older: 2017,
NSDUH.
HEROIN USE
Yes
No
PAIN RELIEVER MISUSE
Yes
0.5%
6.3%
No
0.2%
93.0%
Figure 2: Type of OUD Among Individuals with Past-Year OUD: 2017, NSDUH.

Percent of individuals with OUD

70

65.3%

60
50
40
30
21.6%
20

13%

10
0
Heroin use disorder (HUD)

Pain reliever use disorder (Rx
OUD)

HUD and Rx OUD

Type of opioid use disorder

Pain reliever misuse only, defined by NSDUH as taking an opioid medication in a
manner or dose other than prescribed, was more than thirty times more prevalent than heroin use
only. Overall, 7% of individuals had used heroin and/or misused pain relievers (Table 2).
The prevalence of OUD among individuals surveyed was 0.85%. Of individuals with
OUD, the majority of those were related to prescription pain relievers. There were three times
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more individuals with Rx OUD only than individuals with HUD only. Individuals with both
HUD and Rx OUD represent 13% of individuals with opioid use disorder (Figure 2).
Characteristics of persons with OUD:
Table 3: Characteristics of Individuals by Type of OUD with Past-Year OUD: NSDUH, 2017.
Age
HUD
Rx OUD
HUD and Rx OUD
18-29
55.3%
51.4%
50.0%
30-49
38.8%
37.3%
43.5%
50+
5.8%
11.3%
6.5%
Gender
Male
Female

65.0%
35.0%

52.7%
47.3%

54.8%
45.2%

76.7%
2.9%
1.9%

67.8%
10.9%
2.6%

77.4%
3.2%
3.2%

0.0%

0.3%

0.0%

1.0%
4.9%
12.6%

1.9%
5.1%
11.3%

1.6%
3.2%
11.3%

Family Income
Less than $20,000
$20,000-$49,999
$50,000-$74,999
$75,000 or More

41.7%
28.2%
13.6%
16.5%

27.7%
33.4%
16.7%
22.2%

27.4%
43.5%
12.9%
16.1%

Health Insurance
Private
Public
None

23.3%
47.6%
25.5%

43.2%
55.9%
15.5%

24.2%
45.2%
17.7%

Employment status
Full time
Part-time
Unemployed
Other (e.g. student)

36.9%
11.7%
20.4%
31.3%

43.4%
10.6%
15.8%
30.2%

29.0%
12.9%
21.0%
37.1%

Race
Non-Hispanic White
Non-Hispanic Black
Non-Hispanic Native American/AK
Native
Non-Hispanic Hawaiian/Pacific
Islander
Non-Hispanic Asian
Non-Hispanic more than one race
Hispanic
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Past year major depressive
episode (MDE)
Yes
No

27.5%
72.5%

36.2%
63.8%

34.5%
65.5%

Arrested in the past year
Yes
No

33.0%
67.0%

18.5%
81.5%

42.6%
57.4%

Individuals with OUD in 2017 tended to be younger adults with more than half of those
surveyed between the ages of 18 & 29. More men than women met criteria for each type of
OUD. A high proportion of those with past-year OUD were non-Hispanic white, followed by
Hispanic individuals, and non-Hispanic black individuals. Non-Hispanic Native
Hawaiians/Pacific Islanders represented the smallest portion of individuals with past-year OUD .
Most individuals had some type of insurance, with the greatest proportion being individuals with
some form of public insurance. More than half of those with OUD were employed at least parttime. There was a significant proportion of individuals that were coded as “other” , which
includes individuals that are disabled, keeping house full-time, in school/training, or retired.
One-third of those with OUD reported having had a MDE in the past year. Criminal justice
involvement was also relatively prevalent among those with past-year OUD; 18.5%-42.6% had
been arrested and booked in the past year for offenses beyond minor traffic violations.
Individuals with HUD only tended to be younger, male, non-Hispanic white, lack private
insurance, and had higher rates on unemployment as well as criminal justice involvement. Those
with Rx OUD had the highest percentage of individuals over the age of fifty.
Table 4: Characteristics of Individuals with Past-Year OUD Who Received Treatment for Drug
Use in the Past Year.
Received Treatment
Characteristic
Yes
No
Age
12

18-29
30-49
50+

49.0%
43.9%
7.0%

53.5%
35.7%
10.7%

Gender
Male
Female

52.9%
47.1%

57.1%
42.9%

78.3%
4.5%
2.5%
0.6%

67.4%
10.0%
2.5%
0.0%

0.0%
5.1%
8.9%

2.5%
4.7%
12.9%

Family Income
Less than $20,000
$20,000-$49,999
$50,000-$74,999
$75,000 or More

35.7%
33.8%
12.1%
18.5%

28.2%
33.5%
17.2%
21.0%

Health insurance
Private
Public
Uninsured

28.7%
48.4%
19.2%

40.3%
54.9%
17.4%

Employed

87.9%

89.3%

Major depressive episode
in the past year

32.2%

34.9%

Arrested in the past year

39.0%

17.9%

Number of times arrested
and booked in past 12
months
None
One time
Two times
Three or more times

36.3%
22.3%
10.2%
5.7%

29.5%
10.3%
3.4%
3.8%

Race/ethnicity
White
Black/African American
Native American/AK Native
Native HI/Other Pacific
Islander
Asian
More than one race
Hispanic
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Heroin use disorder

59.9%

22.3%

Table 5: Characteristics of Individuals with Past-Year OUD Associated with Utilizing Treatment
for Drug Use in the Past Year.
Characteristic
Odds Ratio
95% CI
Age (vs. 18-29)
30-49
1.392
0.670 – 2.891
50+
1.871
0.890 – 3.932
Gender (male vs. female)

0.844

0.575 – 1.239

1.675
0.641
1.464

0.878 – 3.196
0.231 – 1.774
0.382 – 5.619

Indeterminate
0.000
1.562

0.000
0.546 – 4.467

1.750
2.615

1.120 – 2.734
1.121 – 6.102

1.675

0.878 – 3.196

Family Income (vs. less
than $20,000)
$20,000-$49,999
$50,000-$74,999
$75,000 or More

1.438
1.144
0.798

0.830 – 2.488
0.663 – 1.976
0.405 – 1.575

Health insurance (yes vs.
no)
Private
Public
Uninsured

0.600
1.295
0.882

0.397 – 0.905
0.883 – 1.899
0.539 – 1.443

Employment (yes vs. no)

0.866

0.477 – 1.574

Major depressive episode
in the past year (yes vs. no)

0.886

0.587 – 1.338

Race/ethnicity (vs. white)
Black/African American
Native American/AK Native
Native HI/Other Pacific
Islander
Asian
More than one race
Hispanic
Race/ethnicity
White vs. non-white
White vs. Black/African
American
White vs. Hispanic
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Arrested in the past year
(yes vs. no)

1.767

Number of times arrested
and booked in past 12
months (vs. none)
One time
2.655
Two times
4.644
Three or more times
6.369
Heroin use disorder (yes vs.
5.212
no)
a
Boldfaced OR, CI: Statistically significant (P<0.05)

1.082 – 2.886

1.634 – 4.315
2.562 – 8.417
2.731 – 14.851
3.445 – 7.885

The largest group of people with past-year OUD who received treatment related to their
drug use were young adults aged 18-29 (49%), predominantly male (52.9%) of non-Hispanic
white ethnicity (78.3%). The majority had some type of health insurance (80.1%), were
employed either part-time or full-time (72.2%), and were in the lowest bracket for family income
(33.8%). Having a history of a MDE in the past year was found among one-third, and 39%
reported some criminal justice involvement in the past year.
In order to determine which characteristics were correlated with drug use treatment
among persons with OUD, logistic regressions were conducted. Odds ratios with 95%
confidence intervals are reported in Table 5 for each logistic regression performed. Age, gender,
NSDUH coded race/ethnicity, employment status, and history of MDE in the past year were not
statistically significant in affecting the odds of individuals with past-year OUD receiving
treatment for drug use. When race/ethnicity was dichotomized, individuals who were nonHispanic white had greater odds of receiving drug use treatment than those who were non-white
(OR 1.750). Compared to individuals who were black, the odds of receiving treatment for drug
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use were more than 2.5 times higher for white individuals. Although having public insurance or
being uninsured were not associated with affecting the odds of using treatment for drug use,
having private insurance was associated with decreased odds of treatment usage (OR 0.600).
Criminal justice involvement was associated with increasing odds of receiving treatment (OR
1.767), with the odds increasing the more times an individual was arrested and booked in the past
12 months (OR increases from 2.655 for being arrested once to 6.369 for being arrested three or
more times). Finally, individuals with past-year HUD had increasing odds of using treatment
related to drug use than those who did not (OR 5.212).
Table 5: Treatment Setting of Individuals with Past-Year OUD Who Received Treatment in the
Past Year.
Treatment location
Percent*
Outpatient rehabilitation
64.3%
Self-help group
54.1%
Mental health facility
42.7%
Inpatient rehabilitation
39.5%
Doctor’s office
36.3%
Hospital inpatient
31.8%
Emergency room
24.2%
Prison/Jail
14.6%
Detox only
13.4%
* Categories do not add to 100% because multiple response options could be selected
Table 5 describes the various settings where individuals with past-year OUD received
treatment related to their drug use in 2017. The most common treatment settings were outpatient
settings, including outpatient rehabilitation (64.3%) and self-help groups (54.1%), such as
Narcotics Anonymous. Short-term treatment settings such as the emergency room and
detoxification alone were less commonly reported (14.6% and 13.4%, respectively).
Table 6: Reasons Why Individuals Did Not Receive Drug Use Treatment
Reason for not receiving treatment
Percent
Could not afford or not insured
7.8%
Not ready to stop using
6.9%
Treatment might have a negative effect on job
4.4%
16

Treatment might cause neighbors/community to have a negative
opinion of you
Insurance doesn’t cover treatment
You thought you could handle the problem without treatment
Didn’t want others to find out you needed treatment
No time (job, childcare, or other commitment)
Didn’t know where to get treatment
Treatment not found for type wanted
No transportation/too far away/inconvenient
No openings
Didn’t think you needed treatment at the time
Lacked motivation
Didn’t think treatment would help

3.1%
2.5%
2.2%
1.6%
1.6%
1.3%
1.3%
0.9%
0.9%
0.9%
0.3%
0.3%

Several of the reasons why people with past-year OUD did not receive treatment for drug
use are highlighted in Table 6. The most common reasons were related to cost. More than 11%
of individuals indicated that they did not receive treatment due to being uninsured, lacking
coverage through their insurance, or not being able to afford treatment. Not being ready to stop
using was a relatively common reason cited among individuals with OUD for not receiving
treatment. Of note, many responders chose to skip this question in the survey.
Discussion
The National Institute on Drug Abuse (NIDA) utilizes the NSDUH to publish current
epidemiological data on drug use in the United States. Heroin use was relatively stable as
reported by 0.1% to 0.2% of the population most years from 2002 to 2008 (Lipari & Hughes,
2014). The data from this report as well as SAMHSA suggested that 0.2 to 0.3% of the
population were current heroin users in 2017, which is an increase from the previous decade
(2018). Although heroin use may not be as common as prescription opioid use, the rise in heroin
use has led to an exponential increase in heroin-related overdose deaths with a 286% increase
from 2002 to 2013 (Hedegaard, Chen, & Warner, 2015). Reasons for this rise include a surge in
17

accidental overdoses related to the circulation of higher purity heroin as well as increasing sales
of much more potent synthetic opioids being sold as heroin (Lipari & Hughes, 2014). Some users
of prescription pain killers for chronic pain may switch over to heroin resulting in accidental
overdoses by unknowingly taking too much, though this is not common among those who abuse
prescription pain relievers. Although this study showed that two-thirds of individuals who used
heroin also misused pain relievers, the majority of individuals who misuse pain relievers never
switch to heroin. One study found that less than 4% of people who had abused prescription
opioids started to use heroin within five years (Muhuri, Gfroerer, & Davies, 2013).
This study highlights the much higher prevalence of prescription opioid misuse than
heroin use. Approximately three million individuals 18 or older were estimated to be current
misusers of pain relievers in 2017 (SAMHSA, 2018), which is less than the estimated 3.5 million
adults that were current misusers of pain relievers in 2015 (CBHSQ, 2016). This decline in
misuse may be for numerous reasons, including federal and state initiatives that have resulted in
a drop in the total number of prescriptions from over 255 million prescriptions in 2012 to 191
million prescription in 2017 (“U.S. Opioid Prescribing Rate Maps,” 2018). Still, prescription
pain reliever use disorder remains the most common category of opioid use disorder which needs
to be addressed through further reduction in prescription rates as well as improving access to
treatment for those with Rx OUD.
By understanding the characteristics of the population that has OUD, prevention efforts
can be better targeted. Persons with OUD tended to be young, non-Hispanic white, and male,
which is consistent with prior analyses of the NSDUH data from 2005 through 2013 (Wu et al.,
2016). Knowing these demographics are associated with Rx OUD is critical to inform efforts to
prevent opioid overdoses, as well as target those who may require treatment for OUD. The other
18

characteristics reported demonstrate the complexity of OUD. Individuals with OUD are more
likely to be unemployed, have a past-year history of criminal justice involvement, and/or pastyear history of a MDE. Beyond the characteristics studied here, further research is needed to
help identify other risk factors significantly associated with OUD.
People with OUD who received treatment for drug use were significantly more likely to
be white compared to minorities altogether as well as compared to African Americans. This is
an example of the greater disparities in healthcare that minorities face (Colby & Ortman, 2015).
Compared with whites, members of racial and ethnic minorities receive care that is often lower
in quality, a result of systematic racism (Hostetter & Klein, 2018). Even when referred to
treatment, blacks and Hispanics are less likely than whites to complete addiction treatment, often
for reasons that are cited in this study, such as cost, access to treatment, and other socioeconomic
factors (Saloner & Cook, 2013). These disparities underline the importance of increasing access
to treatment for minorities as well as addressing any systematic racism that may be negatively
affecting the healthcare provided to minorities.
Another salient finding was that individuals with private insurance had significantly
lower odds of receiving treatment for drug use compared to those without private insurance.
This supports what was reported by Ali & Mutter (2013), who pointed to individuals with private
insurance receiving inadequate coverage and referral for services. A report from the American
Society of Addiction Medicine describes several regulatory barriers among private insurance
policies that hinder access and appropriate care, such as “fail first” criteria that require other
therapies to be attempted prior to initiating medication assisted therapy (Volkow, Frieden, Hyde,
& Cha, 2014). There are often arbitrary limits health insurers have outlined for the duration of
therapy (Volkow et al., 2014). This may stem from the stigma that still exists in healthcare, as
19

well as the general public, that OUD is a moral weakness rather than a disease or illness (Olsen
& Sharfstein, 2014). Such stigma creates a barrier for individuals with OUD to receive the care
they need. Furthermore, reasons for not receiving treatment for OUD included cost or lack of
insurance coverage. As the opioid epidemic continues to impact the lives of millions, it is
critical that treatment be affordable and accessible. This requires patient advocacy and policy
reform through a multidisciplinary approach involving all parties impacted by the opioid
epidemic.
Criminal justice involvement was significantly associated with receiving treatment for
drug use. There were increasingly greater odds of receiving treatment as the number of times
arrested in the past year increased. Courts will often mandate treatment if an offense is related to
drug use (Wu, Blazer, Li, & Woody, 2011). Reform in the criminal justice system has also
increased treatment access among justice-involved individuals due to the high prevalence of
SUD in this population (Saloner et al., 2016). This is also related to Medicaid expansion
through the Affordable Care Act resulting in the uninsured rate among justice-involved
individuals with SUD to decline from 38% to 28% in 2014 (Saloner et al., 2016). However,
treatment received by justice-involved individuals may not be the most effective or evidencebased care. One study found that only 4.6% of justice-referred adults with opioid use disorder
received methadone or buprenorphine, which is significantly lower than the 40.9% of those
referred elsewhere (Krawczyk et al., 2017). Again, this highlights an important population
requiring advocacy for evidence-based treatment.
This study found that individuals with alcohol abuse in the past year were associated with
lower odds of receiving treatment for drug use than individuals who did not have a past-year
history of alcohol abuse. Alcohol abuse may be associated with reduced insight and judgment on
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an individuals problem with other substances as well as the need for treatment. Although alcohol
lowered the odds of receiving treatment, having a past-year history of HUD significantly
increased the odds of receiving treatment for drug use compared to those without a history of
HUD. Heroin may cause more severe adverse outcomes as well as increased chances of
overdose causing the need for treatment to be higher. Also, since heroin is an illicit substance,
its use may result in criminal justice involvement resulting in increased access to treatment.
Since OUD is a chronic disease, treatment for OUD is long-term and occurs in several
settings. Oftentimes individuals may be referred to multiple settings for treatment through the
course of their disease, which is supported by the data showing the various settings utilized by
individuals with OUD. The data also shows that almost a quarter of individuals with OUD
received treatment related to their illicit drug use at an ED. A recent CDC report stated that there
was a 30% increase in ED opioid overdose visits from 2016 to 2017, which reflects an increase
in death rates from opioids (“Emergency Department Data Show Rapid Increases in Opioid
Overdoses,” 2018). The increase in ED visits from opioid overdoses may be an area to improve
treatment utilization through increased referral to other treatment settings as well as the initiation
of medication assisted therapy, such as buprenorphine/naloxone. Although an area of current
debate and controversy, initiation of medication assisted therapy in the ED was found in a
randomized clinical trial to increase engagement in addiction treatment as well as reduce
subsequent self-reported illicit opioid use (D’Onofrio et al., 2015).
Study limitations
There are several limitations to this study. First, self-report data on illicit drug use may
be underreported, introducing recall bias. Generally, studies have supported the validity of selfreported data on substance use (Harrison, 1997). Other procedures to measure drug use (such as
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testing biological specimens) are often too expensive and impractical to perform for general
population epidemiological studies (SRNT Subcommittee on Biochemical Verification, 2002).
Second, treatment related to illicit drug use was measured as the outcome variable rather than
treatment specific for OUD. Chi-square analysis of these two variables suggested that they were
so correlated with on one another that the Phi-value was approximating 1.0 (not shown).
Nonetheless, some external validity might be limited due to inclusion of all illicit drug use
treatment as the outcome rather than only opioid-specific treatment. Another limitation is that
the logistic regressions were all conducted independently for each characteristics. When
combined, the variance in receipt of treatment accounted for by each characteristic was
attenuated to statistically insignificant findings for odds ratios (not shown). Further studies will
need to control for the variance accounted for from each characteristic to determine the extent in
which they impact treatment utilization. Finally, external validity is also limited due to the
exclusion of non-civilians and non-institutionalized individuals, which is approximately 3% of
the US population (Center for Behavioral Health Statistics and Quality, 2016). People missed by
the NSDUH include individuals who are homeless, incarcerated, or hospitalized, which may be
at higher risk for OUD.
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